Author:
Bolis Giorgio,Scarfone Giovanna,Sciatta Cesarina,Polverino Gian Piero,Rosa Cristina,Guarnerio Paolo,Parazzini Fabio
Subject
Obstetrics and Gynaecology,Oncology
Reference21 articles.
1. A phase 11 study of oral topotecan as a single agent, second-line therapy administered for five days in patients with advanced ovarian cancer;Clarke-Pearson;Proc Am Soc Clin Oncol,1998
2. Chemotherapy in patients (pts) with small residual disease (SRD) after Taxol–carboplatin (TC) as first line chemotherapy in advanced epithelial ovarian cancer (AEOC);Scarfone;Proc Am Soc Clin Oncol,1998
3. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer;Ten Bokkel Huinink;J Clin Oncol,1997
4. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase 11 study;Creemers;J Clin Oncol,1996
5. Phase 11 study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma;Kudelka;J Clin Oncol,1996
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献